Viral Vector Formulation & Process Development Europe -Now Live

Unlock Viral Vector-Based Therapeutics Opportunities through Optimised Formulation, Process Development with Scalability

With the exciting news of Astellas licensing 4DMT’s viral vector for gene therapy for up to $962m, viral vector-based therapies continue to grow. According to our Beacon tracker, there are currently 829 clinically active viral vector-based drugs, split across 184 in AAV and 418 using lentivirus.

As biopharma looks to leverage viral vector for common diseases and commercialisation, there is an urgent need for viral vector process development experts to unite, seeking solutions to:

  • Optimise formulation to enhance stability
  • Improve process intensification across up- and downstream for maximum yield
  • Integrate advance process analytical development techniques for functional particles and product quality
  • Reduce COGS, in particular raw materials, to make these novel therapies accessible and affordable for patients
  • Adhere to GMP compliance for patient safety and smooth approval process

The Viral Vector Formulation & Process Development Summit Europe recognises the above challenges, and it’s our aspiration to help you find answers to these burning questions. Emulating on our US community’s success, we are the only definitive, end-to-end platform to unite 60+ viral vector leaders in the MSAT, Tech Ops, Process Development and Formulation teams to share their lessons learned and journeys to-date:

  • rAAVen Therapeutics will discuss how to advance capsid engineering to enhance stability of your vector
  • Janssen & Vironova BioAnalytics to reveal characterisation of AAVs and other gene therapy vectors using TEM to assess CQAs
  • Hookipa Pharma will share how to ensure compliance through particle analysis and formulation of viral vectors relating to ATMPs regulatory requirements
  • UCB will help you overcome downstream process development and manufacturing of rAAV
  • Lokon Pharma will set out the right criteria for CDMO partners, and how to overcome capacity and availability for viral vector production for speed-to-patient


In collaboration with the likes of VectorY, Roche, Janssen, UCB, this 2-day summit will equip you with practical takeaways across LV, AAV, RSV pioneers, and set your 2024 up for success – fast tracking your pipeline progression with best-in-class cell, gene and vaccine therapies for patients in need.

Your 5 Unmissable Keynotes at this Event to Transform Your Viral Vector Process Development & Pipeline Progression:

Inspire up- and downstream process innovations across different viral vector candidates to improve manufacturability – specifically LV, AV and AAV, giving you the insight to adopt novel process development capabilities with host cell line selection, triple transfection and purification

Evaluate the impact of the revised EU Annex 1, and standardise assay and reference materials for viral vector manufacturing

Optimise viral vector formulation to maximise stability, increase storage temperature, CMC and streamline scalability

Assess advanced capsid engineering’s implications on process development, rapid scale-up to improve yield and decrease COGs

Discuss pre-competitive partnership models to accelerate speed-to-clinic and patient

Industry Leading Speakers Include:

Proud to Partner With:

SGS Vitrology

Viral Vector Process Development Community Members Include: